Photocurable Collagen Filler Aims to Address Weight-Loss–Associated Facial Deflation

CollPlant Biotechnologies announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss associated with rapid weight reduction, including in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RA) for metabolic health and weight management.

The expanding use of GLP-1 RA–based therapies has coincided with increased reports of facial fat atrophy, midface deflation, jawline softening, and skin laxity following significant weight loss. In a company statement, CollPlant described this presentation as weight-loss–related facial volume depletion and identified it as an emerging aesthetic indication.

CollPlant’s photocurable dermal filler is based on recombinant human collagen (rhCollagen) and is designed to provide immediate structural restoration. According to the company, the product forms a crosslinked scaffold in situ following light activation, with the intent of supporting tissue integration and potentially improving skin quality and elasticity over time. The technology remains in the preclinical stage of development.

"Rapid weight loss can lead to significant facial volume depletion and skin quality changes," said Yehiel Tal, Chief Executive Officer of CollPlant. "GLP-1 RA therapies are creating a new category of aesthetic indications. CollPlant's photocurable filler technology was designed for structural tissue restoration—making it particularly relevant for patients experiencing rapid facial volume loss. Our photocurable rhCollagen-based filler platform is designed not only to restore facial contours, but also to provide a scaffold to support tissue regeneration and long-term structural improvement."

Jason Bloom, MD, a double board-certified facial plastic surgeon, commented in the announcement that clinicians are observing an increasing number of patients presenting with facial volume depletion after substantial weight loss, particularly among those using newer metabolic therapies. He noted that technologies aimed at supporting tissue integration and regeneration may represent an evolution beyond temporary filling approaches.

CollPlant stated that it is continuing to evaluate clinical and commercial pathways for the platform as part of its broader regenerative aesthetics strategy.